Highlights 

  • INOVIO intends to sell shares of common stock through an underwritten public offering. 
  • Underwriter granted 30-day option to purchase additional shares up to 15% of the offering. 
  • The offer is subject to market conditions, with timing and size. 

INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company developing DNA medicines targeting HPV-related diseases, cancer, and infectious diseases, announced its plans to conduct a public offering of its common stock. All shares in the offering will be sold by the company, which will also grant the underwriter a 30-day option to purchase additional shares equal to up to 15% of the total offering under the same conditions. 

The offering is contingent on prevailing market conditions, and there is no certainty regarding the timing, size, or completion of the transaction. Piper Sandler & Co. will act as the sole book-running manager for the offering. 

Regulatory Filings and Prospectus 

INOVIO previously filed a shelf registration statement with the U.S. Securities and Exchange Commission on November 9, 2023, which was declared effective on January 31, 2024. The offering will be conducted exclusively through a written prospectus and prospectus supplement, forming part of the registration statement.  

Company Overview 

INOVIO is a biotechnology company dedicated to the development and commercialization of DNA medicines aimed at treating and preventing HPV-related diseases, cancer, and infectious diseases. Its proprietary technology platform is designed to optimize the design and delivery of DNA-based therapies, enabling the body to generate its own targeted immune responses. 

The company has advanced multiple DNA medicine programs focused on both preventive and therapeutic applications. INOVIO continues to explore new applications for its technology while maintaining compliance with U.S. securities regulations in its capital-raising initiatives, such as this proposed public offering. 

Next Steps 

Investors considering participation in the offering will need to review the final prospectus and prospectus supplement when filed with the SEC. Market conditions and regulatory approvals will determine the timing and execution of the public offering, including the underwriter’s potential exercise of the 30-day option to purchase additional shares.